NIXOVA Ltd.

Report for Investors,

To gain the faith of our investors and other stakeholders, we are continuously working and
striving to achieve something great and want to maximize our investor’s wealth and want to
make a positive impact on the society, unlike all other businesses, the Pharma business is
much more crucial as we are saving the life of people, and working hard to make & win our
customer’s faith and trust.

“We are NIXOVA LTD., we are more than a business we are saviors”

As we know in the recent times in particularly in covid times our company is facing many
allegations in which many are biased and fake, we are not going to entertain them but as a
responsible organization, as we care our investors a lot we are today announcing our balance
sheet report that, how well we are performing and how our balance shows a clear win-win
situation for both the company and the investors.

Assumptions,

 The balance sheet has data on only the Oxcitrol.

 The balance sheet is prepared by comparing various pharma companies, as no data
was given in the case study.
 Balance sheet is prepared with a view of international factors
 Further assumptions,
 Includes only the sales of Oxcitrol
 Estimated Sales units, 2cr
 Per unit price, 35 per unit
 2cr x Rs. 35 = 70cr sales
 Cost to produce is 20
 Estimated cost, 2cr x Rs. 20 = 40cr
 Growth Estimated 12% P.A.
 Profit 30Cr.
 The balance sheet of NIXOVA Ltd., (* data is in Crores)

EQUITIES AND LIABILITIES

SHAREHOLDER'S FUNDS
Equity Share Capital 10

Total Share Capital 10

Reserves and Surplus 100

Total Reserves and Surplus 100

Total Shareholders’ Funds 110

NON-CURRENT LIABILITIES

Long Term Borrowings 0.2

Other Long-Term Liabilities 0

Long Term Provisions 0

Total Non-Current Liabilities 0.2

CURRENT LIABILITIES

Short Term Borrowings 2

Trade Payables 50

Other Current Liabilities 0

Short Term Provisions 0

Total Current Liabilities 52

Total Capital and Liabilities 162.2

ASSETS

NON-CURRENT ASSETS

Tangible Assets 50

Intangible Assets 5

Capital Work-In-Progress 0
Intangible Assets Under 0
Development
Fixed Assets 55

Non-Current Investments 10

Deferred Tax Assets [Net] 0

Long Term Loans and Advances 10

Other Non-Current Assets 0

Total Non-Current Assets 20

CURRENT ASSETS

Current Investments 10

Inventories 10

Trade Receivables 5

Cash And Cash Equivalents 50

Short Term Loans and Advances 2.2

Other Current Assets 10

Total Current Assets 87.2

Total Assets 162.2

 From the above balance sheet, we can clearly see that our company is financially
sound and healthy, as we can see that the company has a huge reserve that it will use
to expand its operations further in China, and will use to attract govt. tender to
provide Oxcitrol in huge quantity. Our company’s liquidity position is great that we
are able to cover all our short-term obligations.
We are planning to raise a further 50 cr as equity from retail investors through FPO,
and the company’s long-term borrowings are negligible at 20lacs and also with a
good credit history company may also get loans from various financial institutions (if
required).
The trade receivables of the company are only 5cr which shows that the company
has a great debtor turnover, and the default is near zero. And also, the trade payables
are lower than the industry average. The company is also getting a return of 14-15%
regularly on its external investments.
And we are continuously making wealth maximization of our investors, and also
providing good returns on stock from the market and a regular dividend payout
policy.
 Fund Allocation,

Chart Title
20; 22%
5; 6%

5; 6%

50; 56% 10; 11%

Govt. tender Reserve Talent Acquistion

Facility Expansion Marketing & PR